SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ray Charles Synthetic CCD

PatientRay Charles
Date of birth1960-09-23
IdentifiersMRN HR-ML009-SYN; SSN (made up) 000-09-5561
Document date2026-11-01
AuthorGloria Fenwick, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening. Concerns: He wants his records and instructions in a form he can read himself, without having to rely on someone else; He wants any future pain treated without putting his long recovery at risk. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrilsOne spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911Nasal route2026-03-03activeS

Procedures

ProcedureDatesStatusEvidence
Ophthalmic examination of the blind eyes for comfort and complications2026-03-31 to 2026-03-31completedS
Advance care planning conversation, about 20 minutes2026-10-06 to 2026-10-06completedS

Immunizations

DateVaccineStatusEvidence
2025-10-20High-dose influenza vaccine, 2025-2026 seasoncompletedS
2026-10-06High-dose influenza vaccine, 2026-2027 seasoncompletedS
2026-10-06Pneumococcal conjugate vaccine PCV20completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1937Gradual loss of sight from about age five; blind by age seven; schooled at the Florida School for the Deaf and BlindD (CLM-0003)
1937Cause of the childhood blindness never diagnosed, by his own account; congenital juvenile glaucoma is the cause most often suggestedR (CLM-0004)
1965Heroin addiction from the late 1940s, publicly admitted after an arrest in 1964; stopped in 1965 after rehabilitation at a California sanitariumD (CLM-0005, CLM-0006)

Family History

RelativeConditionAge at deathEvidence
motherDied in 1945; cause not recorded in the cited sourceD (CLM-0007)
brotherYounger brother died by drowning in early childhoodD (CLM-0007)

Health Concerns

ConcernStatusEvidence
He wants his records and instructions in a form he can read himself, without having to rely on someone elseactiveS
He wants any future pain treated without putting his long recovery at riskactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.2 on 2026-03-03; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-03; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-03-03; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 84 on 2026-03-03; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-03-03; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-03-03; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-03-03; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-03-03; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 110 on 2026-03-03; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-03-03; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-03-03; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-09-01; Total score [AUDIT-C] 2 on 2026-10-06; Total score [DAST-10] 0 on 2026-10-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06 [S]

Strengths and supports: Recovery supports: purposeful work, long-time colleagues, and friends; has not needed formal recovery services for many years and knows how to reach them [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Blindness of both eyes since childhood, no light perception; cause never diagnosedactiveconfirmed H54.0X55S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness.
Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatmentactiveconfirmed F11.21S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-03Hemoglobin [Mass/volume] in Blood14.2g/dL13.2-16.6 g/dLNormalS
2026-03-03Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-03Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-03-03Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
2026-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-03Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-03-03Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-03-03Cholesterol [Mass/volume] in Serum or Plasma186mg/dL<=200 mg/dLNormalS
2026-03-03Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=40 mg/dLNormalS
2026-03-03Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation110mg/dL<=129 mg/dLNormalS
2026-03-03Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-03-03Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2026-03-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-03-03Total score [AUDIT-C]2{score}S
2026-03-03Total score [DAST-10]0{score}S
2026-09-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-06Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-06Total score [AUDIT-C]2{score}S
2026-10-06Total score [DAST-10]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-03Body height178cmS
2026-03-03Body weight80kgS
2026-03-03Body mass index (BMI) [Ratio]25.2kg/m2S
2026-03-03Systolic blood pressure128mm[Hg]S
2026-03-03Diastolic blood pressure78mm[Hg]S
2026-03-03Heart rate68/minS
2026-03-03Respiratory rate14/minS
2026-03-03Body temperature36.7CelS
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-03-31Body height178cmS
2026-03-31Body weight80.2kgS
2026-03-31Body mass index (BMI) [Ratio]25.3kg/m2S
2026-03-31Systolic blood pressure126mm[Hg]S
2026-03-31Diastolic blood pressure76mm[Hg]S
2026-03-31Heart rate66/minS
2026-03-31Respiratory rate14/minS
2026-03-31Body temperature36.6CelS
2026-03-31Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-06-02Body height178cmS
2026-06-02Body weight79.8kgS
2026-06-02Body mass index (BMI) [Ratio]25.2kg/m2S
2026-06-02Systolic blood pressure124mm[Hg]S
2026-06-02Diastolic blood pressure78mm[Hg]S
2026-06-02Heart rate68/minS
2026-06-02Respiratory rate14/minS
2026-06-02Body temperature36.7CelS
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-01Body height178cmS
2026-09-01Body weight80kgS
2026-09-01Body mass index (BMI) [Ratio]25.2kg/m2S
2026-09-01Systolic blood pressure128mm[Hg]S
2026-09-01Diastolic blood pressure76mm[Hg]S
2026-09-01Heart rate66/minS
2026-09-01Respiratory rate14/minS
2026-09-01Body temperature36.6CelS
2026-09-01Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-06Body height178cmS
2026-10-06Body weight80.4kgS
2026-10-06Body mass index (BMI) [Ratio]25.4kg/m2S
2026-10-06Systolic blood pressure126mm[Hg]S
2026-10-06Diastolic blood pressure78mm[Hg]S
2026-10-06Heart rate68/minS
2026-10-06Respiratory rate14/minS
2026-10-06Body temperature36.7CelS
2026-10-06Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-03-03Establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screeningfinishedS
2026-03-31Four-week follow-up with ophthalmology consultation for the blind eyesfinishedS
2026-06-02Three-month review of recovery, accessibility, and fall preventionfinishedS
2026-09-01Six-month review with depression screening and a plan for any future painfinishedS
2026-10-06Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Disability-competent care at every visit: introductions and spoken orientation, describing each step of the examination, offering an arm for guiding, and all documents in an accessible electronic formatcompletedGL-AAO-VISREHAB-2023S
Ophthalmology consultation to examine the blind eyes for comfort and complications and to advise on pressure checks and surveillancecompletedGL-AAO-POAG-2025, GL-CMID-2026S
Recovery-oriented care: ask about cravings, triggers, and any return to use at each visit in a non-judgmental way; naloxone at home and when traveling; recovery supports he can reach; and a written plan for any future paincompletedGL-SUD-2021, GL-ASAM-OUD-2020S
Depression screening with the PHQ-9 at intake and at six months, PHQ-2 at the wellness visit, and a safety review with the 988 Suicide & Crisis Lifeline at each visitcompletedGL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024S
Medicine labeling: audio labels from the pharmacy, a braille label on the naloxone, and the same pharmacy for every prescriptioncompletedGL-AAO-VISREHAB-2023S
Fall prevention: CDC STEADI screen at each visit, keeping the home layout unchanged, and a sighted guide in unfamiliar placescompletedGL-AAO-VISREHAB-2023S

Goals

GoalTargetStatusOutcomeProvenance
Visit summaries, results, and medicine information delivered in an accessible electronic format, and medicine labels in braille or audio, by the four-week visit2026-03-31completedVisit summaries sent as accessible documents; the pharmacy provides audio labels and a braille label on the naloxoneS
Naloxone at home and in his travel bag, with a tactile label, and the people he travels with shown how to use it, by the three-month visit2026-06-02completedNaloxone in both places; travel staff shown how to use itS
Stay in sustained remission, with no return to opioid use, through six months2026-09-01completedNo opioid use; DAST-10 0 at intake and no use reported at each visitS
No falls through six months2026-09-01completedNo fallsS
A written plan for any future acute pain or surgery that uses non-opioid treatment first and builds in safeguards if an opioid is ever needed, by the six-month visit2026-09-01completedPlan written with him and saved in an accessible formatS

Functional Status

Mental Status

Structured synthetic safety assessment on 2026-03-03: current ideation absent, intent absent, plan absent. Routine outpatient care. Crisis resources, including the 988 Suicide & Crisis Lifeline, given in an accessible electronic format and saved in his phone; safety reviewed at each visit [S]